PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options.

Abstract Focal nodular hyperplasia (FNH) is the second most common benign tumor of the liver. As of 2017, many clinical, radiological and surgical features have been largely documented. On the other hand, little is still known about the correlation of FNH with hepatocellular carcinoma, nor the preferable modality of treatment. Our aim was to elucidate the latter topic.
PMID
Related Publications

Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis.

Transarterial embolization using pingyangmycin lipiodol emulsion and polyvinyl alcohol for the treatment of focal nodular hyperplasia of the liver.

Transarterial embolization as a therapeutic option for focal nodular hyperplasia in four patients.

Super selective transcatheter arterial embolization for treatment of focal nodular hyperplasia of the liver: report of 21 cases.

Transarterial embolisation of a large focal nodular hyperplasia, using microspheres, in a paediatric patient.

Authors

Mayor MeshTerms
Keywords

FNH

Focal nodular hyperplasia

HCC

TAE

hepatocellular carcinoma

review

transarterial embolization

Journal Title anticancer research
Publication Year Start




PMID- 29277753
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive
      Approaches? A Review of the Preferable Treatment Options.
PG  - 33-36
AB  - BACKGROUND/AIM: Focal nodular hyperplasia (FNH) is the second most common benign 
      tumor of the liver. As of 2017, many clinical, radiological and surgical features
      have been largely documented. On the other hand, little is still known about the 
      correlation of FNH with hepatocellular carcinoma, nor the preferable modality of 
      treatment. Our aim was to elucidate the latter topic. MATERIALS AND METHODS: We
      investigated the pertinent literature available as of 2017 through four popular
      search engines (PubMed, Science Direct, Scopus and Google Scholar). Four main
      approaches were selected: conservative treatment, surgery, radiofrequency
      ablation (RFA) and transarterial embolization (TAE). RESULTS: We found most works
      to be on conservative and surgical approaches. On the contrary, only one article 
      has been published for RFA to date. Seventeen articles dealt with TAE.
      CONCLUSION: TAE currently represents the most cogent and successful alternative
      to surgery.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Virgilio, Edoardo
AU  - Virgilio E
AD  - Department of Medical and Surgical Sciences and Translational Medicine, St.
      Andrea Hospital, Faculty of Medicine and Psychology, Sapienza University, Rome,
      Italy [email protected] [email protected]
FAU - Cavallini, Marco
AU  - Cavallini M
AD  - Department of Medical and Surgical Sciences and Translational Medicine, St.
      Andrea Hospital, Faculty of Medicine and Psychology, Sapienza University, Rome,
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Catheter Ablation
MH  - Embolization, Therapeutic
MH  - Focal Nodular Hyperplasia/surgery/*therapy
MH  - Humans
MH  - Liver/*pathology/surgery
OTO - NOTNLM
OT  - *FNH
OT  - *Focal nodular hyperplasia
OT  - *HCC
OT  - *TAE
OT  - *hepatocellular carcinoma
OT  - *review
OT  - *transarterial embolization
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/14 00:00 [received]
PHST- 2017/10/31 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/33 [pii]
AID - 10.21873/anticanres.12188 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):33-36. doi: 10.21873/anticanres.12188.